APPENDIX B: Key Question 1 Evidence to Decision Table

QUESTION

Should MWA ablation (laparoscopic or open) vs. RFA ablation (laparoscopic or open) be used for HCC or CRLM less than 5cm?					
POPULATION:	HCC or CRLM less than 5cm				
INTERVENTION:	MWA ablation (laparoscopic or open)				
COMPARISON:	RFA ablation (laparoscopic or open)				
MAIN OUTCOMES:	Perioperative Complications; Disease Free Survival 1yr; Disease Free Survival 3 yr; Disease Free Survival 5yr; Incomplete Ablation; Overall Survival 1yr; Overall Survival 3yr; Overall Survival 5yr; Local/Regional Reccurence;				
SETTING:					
PERSPECTIVE:	PATIENT-CENTERED				
BACKGROUND:					
CONFLICT OF INTERESTS:					

ASSESSMENT

Problem Is the problem a priority?							
JUDGEMENT	RESEARCH EVIC	DENCE					ADDITIONAL CONSIDERATIONS
o No o Probably no o Probably yes • Yes o Varies o Don't know							
	Desirable Effects How substantial are the desirable anticipated effects?						
JUDGEMENT							ADDITIONAL CONSIDERATIONS
o Trivial ■ Small o Moderate	Vote: 80% (8/10)						
O Large O Varies O Don't know		Certainty of the evidence	Relative effect (95% CI)	Anticipated absolute effects* (95% CI)			
O BOIL KNOW		(GRADE)		Risk with RFA ablation (laparoscopic or open)	Risk difference with MWA ablation (laparoscopic or open)		
					Study population	on	

Perioperative Complications	882 (8 observational studies)	⊕○○○ Very low ^{a,b}	RR 0.98 (0.72 to 1.33)	165 per 1,000	3 fewer per 1,000 (46 fewer to 54 more)
Disease Free	177	ФООО	RR	Study population	on
Survival 5yr	(4 observational studies)	Very low ^{a,b}	1.09 (0.79 to 1.51)	358 per 1,000	32 more per 1,000 (75 fewer to 183 more)
Incomplete	715	ФООО	RR	Study population	
Adiation	Ablation (6 observational studies)	Very low ^{a,b}	0.92 (0.40 to 2.11)	35 per 1,000	3 fewer per 1,000 (21 fewer to 39 more)
Overall	782	ФООО	RR	Study population	
Survival 5yr	(6 observational studies)	Very low ^{a,b}	1.01 (0.91 to 1.11)	660 per 1,000	7 more per 1,000 (59 fewer to 73 more)
Local/Regional	668	ФООО	RR	Study population	
Reccurence	studies) (0.		0.97 (0.73 to 1.30)	360 per 1,000	11 fewer per 1,000 (97 fewer to 108 more)

- a. There were several larger studies that had a high risk of bias due to baseline differences in the cohorts that were not controlled for with statistical matching.
- b. In addition to having a small event rate, the range of estimated effects crossed several clinically meaningful thresholds from important benefits to important harms.

Undesirable Effects

How substantial are the undesirable anticipated effects?

JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
o Large o Moderate o Small o Trivial o Varies • Don't know	There were no undesirable effects for the important or critical outcomes. Vote: 100% (10/10)	

Certainty of evidence
What is the overall certainty of the evidence of effects?

JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS				
• Very low	Vote: 100% (10/10)					
o Low o Moderate	Outcomes	Importance	Certainty of the evidence (GRADE)			
HighNo includedstudies	Perioperative Complications	CRITICAL	⊕⊖⊖⊖ Very low ^{a,b}			
	Disease Free Survival 5yr	CRITICAL	⊕○○○ Very low ^{a,b}			
	Incomplete Ablation	IMPORTANT	⊕○○○ Very low ^{a,b}			
	Overall Survival 5yr	CRITICAL	⊕○○○ Very low ^{a,b}			
	Local/Regional Reccurence	IMPORTANT	⊕⊖⊖ Very low ^{a,b}			
Values	to baseline difference with statistical match					
Is there important i	uncertainty about or variability in how i	nuch people value the	e main outcomes?	1		
JUDGEMENT	RESEARCH EVIDENCE			ADDITIONAL CONSIDERATIONS		
o Important uncertainty or variability o Possibly important uncertainty or variability o Probably no important uncertainty or variability • No important uncertainty or variability	Vote: 90% (9/10)					
Balance of effects Does the balance between desirable and undesirable effects favor the intervention or the comparison?						
JUDGEMENT	RESEARCH EVIDENCE			ADDITIONAL CONSIDERATIONS		

o Favors the comparison o Probably favors the comparison o Does not favor either the intervention or the comparison • Probably favors the intervention o Favors the intervention o Varies o Don't know	Vote: 100% (9/9)	
Acceptabilit	acceptable to key stakeholders?	
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
o No o Probably no ● Probably yes o Yes o Varies o Don't know	Vote: 100% (9/9)	
Feasibility Is the intervention	feasible to implement?	
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
o No o Probably no ● Probably yes o Yes o Varies o Don't know	Vote: 100% (9/9)	MWA easier to use than RFA (Difficult equipment to use) MWA more expensive than RFA

SUMMARY OF JUDGEMENTS

	JUDGEMENT						
PROBLEM	No	Probably no	Probably yes	Yes		Varies	Don't know
DESIRABLE EFFECTS	Trivial	Small	Moderate	Large		Varies	Don't know
UNDESIRABLE EFFECTS	Large	Moderate	Small	Trivial		Varies	Don't know
CERTAINTY OF EVIDENCE	Very low	Low	Moderate	High			No included studies
VALUES	Important uncertainty or variability	Possibly important uncertainty or variability	Probably no important uncertainty or variability	No important uncertainty or variability			

	JUDGEMENT						
BALANCE OF EFFECTS	Favors the comparison	Probably favors the comparison	Does not favor either the intervention or the comparison	Probably favors the intervention	Favors the intervention	Varies	Don't know
ACCEPTABILITY	No	Probably no	Probably yes	Yes		Varies	Don't know
FEASIBILITY	No	Probably no	Probably yes	Yes		Varies	Don't know

TYPE OF RECOMMENDATION

Strong recommendation against the intervention	Conditional recommendation against the intervention	Conditional recommendation for either the intervention or the comparison		Strong recommendation for the intervention
0	0	0	•	0

CONCLUSIONS

Recommendation

Final Vote: 89% (8/9)

Justification

Subgroup considerations

Implementation considerations

Monitoring and evaluation

Research priorities

- Studies need to be clearer in their definitions of outcomes (i.e. local regional recurrence at the site of treatment vs. anywhere in liver \Diamond Ablation vs. disease problem)
- May be necessary to study HCC and CRLM separately
- -similar surgical procedures
- -Subgroup other neoplasms of liver
- -Selection bias within Ablation and approach
- -Long term follow up of studies needed in more studies
- -RCT comparing MWA vs. RFA
- -Larger studies powered to detect difference
- -Cancer specific survival vs. overall survival especially in HCC
- -Need to standardize definitions of locoregional recurrence based on treatment vs. disease